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Abstract  
 
Objective:  This review assesses the evidence for the cost-effectiveness of health behaviour 
interventions that address the major behavioural risk factors for chronic disease including; 
smoking, physical inactivity, poor diet and alcohol misuse. Methods:  Medical and economic 
databases were searched for relevant economic evaluations.  Studies were critically appraised 
using a published 35-point checklist, and the results are described using a narrative approach, 
noting methodological limitations. The review included 64 studies from 1995-2005, including 
17 reports on multiple behaviour interventions. Results:  There was considerable variation 
among the studies by target populations, intervention components, primary outcomes and 
economic methods, yet the reported incremental cost-effectiveness ratios were consistently 
low (e.g., <€14,000 per quality-adjusted life year gained for smoking-cessation programs in 
2006 Euros) compared to certain preventive pharmaceutical and invasive interventions.  
Interventions targeting high-risk population sub-groups were relatively better value for 
money  compared to those targeting general populations. Discussion:  In general, results of 
this review demonstrate favourable cost-effectiveness for smoking interventions, physical 
activity interventions and multiple behaviour interventions in high-risk groups.  For alcohol 
and dietary interventions, although appearing economically favourable, conclusions are 
difficult due to the variety in study outcomes.    However, methodological limitations weaken 
the generalisability of findings, and suggest that the results of any given study be considered 
carefully when being used to inform resource allocation.  
 
Keywords: cost-effectiveness, smoking cessation, physical activity, diet, alcohol intake 
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Introduction   
 
In the Western world, the key behaviours contributing to the largest disease burden include: 
tobacco smoking, physical inactivity, poor diet, harmful alcohol intake, drug use, vaccination 
practices and sexual behaviours.1-4  In the US, for example, the primary causes of death in 
2000 were from tobacco smoking (18%), poor diet and physical inactivity (16%) and alcohol 
consumption (3.5%).2  Unlike other factors that impact upon health outcomes, such as genetic 
predisposition, ageing or cultural background, these health behaviours are potentially 
avoidable and modifiable.  Clearly, a more preventive approach to health is crucial if public 
health is to improve in any sizeable way.2  Despite a substantial body of literature confirming 
the efficacy of health behaviour interventions in smoking, physical activity, dietary intake 
and alcohol,5-10 translating these interventions into public health practice has been limited.   
Health behaviour interventions are the best way to both prevent and manage chronic disease.  
The current emphasis in the health behaviour intervention field is on converting this evidence 
into practice.11  A key issue in this regard is the need for data on the cost-effectiveness of 
interventions to allow health care policy makers to make informed decisions about the value 
of such interventions.   
 
Three reviews exist on the economic evaluation results of smoking-cessation strategies.12-14  
An early review by Warner et al. (1997) concluded that smoking-cessation interventions 
delivered by general practitioners were highly cost-effective and remained the ‘gold-
standard’ in cost-effective health care. Similar conclusions were made by Woolacott et al. 
(2002) reviewing interventions with multiple strategies delivered by a range of health 
professionals, and targeting specific types of smokers and an emphasis on pharmacologic 
approaches and routine clinical care settings. In an attempt to improve the generalisability of 
cost-effectiveness findings from smoking-cessation programs, Ronckers et al. (2005) re-
analysed findings to generate standardized cost-effectiveness ratios across settings, to help 
eliminate variation in program effects and costing methods.  However, huge variation among 
cost-effective ratios remained (i.e., $US 490 - $15,280 life-years saved (LYS). 12 Compared 
to many pharmaceutical treatments, surgeries and hospital-based health care services, the 
general consensus is that smoking-cessation strategies represent excellent health care 
investment.12, 13, 15  
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Four other reviews on the cost-effectiveness of preventive interventions are aimed at specific 
diseases: diabetes, 16 coronary heart disease, 17, 18 and artherosclerosis.19  Addressing 
behavioural modification interventions for diabetes, Vijgen et al. (2006) reviewed three older 
studies on diabetes management and concluded more research was needed although noted the 
findings supported their cost-effectiveness.16  Similarly, Brown et al. (1998, 2002) reviewed 
seven pre-1995 studies on coronary heart disease prevention, focussing on primary 
prevention strategies for smoking-cessation and physical activity, and confirmed that GP-
delivered smoking-cessation interventions were highly cost-effective, but that further 
evaluations were needed for physical activity interventions.   
 
The aim of this review is to assess the evidence from economic evaluations of face-to-face 
behaviour interventions for smoking, physical inactivity, poor diet, and alcohol misuse from 
reports published during1995-2005.  This review provides a unique addition to the literature 
by consolidating the economic evaluation literature for all four behaviours, something not 
done in any previous review.   We have focused the review on interventions delivered 
through face-to-face methods because this provides a more homogenous group of 
interventions for comparison purposes, and because this was the most common intervention 
method during the period covered by the review.   
   
Review Methods 
 
Interventions were included if (1) they were an economic evaluation of a health behaviour 
change intervention for tobacco smoking or diet or physical activity or alcohol misuse 
behaviours or any combination of these behaviours; (2) interventions were delivered face-to-
face; (3) interventions were aimed at individual-level behaviour change (rather than system-
level or environmental changes e.g., mass media campaigns); and (4) studies were published 
in the English language from 1995 to 2005 inclusive.  We have included studies involving 
behaviour change interventions if they were the either the focus of the study or one of the 
comparator interventions, because face-to-face behavioural interventions are often used in 
conjunction with other technologies (i.e., pharmacotherapies, surgeries).  This time frame was 
chosen because standardized methods for the conduct and reporting of economic evaluations 
in health care were not available until 1987 and were not widely adopted until several years 
later.20  We excluded non-English language studies because we did not have the resources to 
translate these reports.  Both studies of healthy populations (i.e., primary prevention) and 
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those with or at risk of a disease (i.e., secondary prevention) were included.  Furthermore, 
where studies involve persons with or at risk of disease, we have focussed on cardiovascular 
diseases, obesity, diabetes and cancer, because they incur the most costly health burdens in 
developed nations.  For reports of interventions where two papers were published on the 
same study but report on different effectiveness measures , we have included only one report, 
and favoured outcomes in the generic outcome measure ‘quality-adjusted life years gained’ 
(QALYs).  Studies were excluded if the report had insufficient data to assess the economic 
evaluation, that is, one or two brief paragraphs on the economic methods and outcomes.  
Partial economic evaluations do not provide efficiency information for resource allocation 
decisions therefore these studies were excluded.  Specifically, this meant that studies 
describing only the costs of the intervention without health outcomes or studies that evaluated 
the costs and health benefits of one intervention with no mention of a comparator(s) were 
excluded.  In addition, to preserve the quality of the studies chosen for the review, we also 
excluded studies that did not synthesize cost and health outcomes data into a summary 
measure for the economic evaluation, that is, no cost-effectiveness ratios were produced.   
 
In the first instance, the National Health Service-Economic Evaluation Database (NHS-EED) 
http://www.york.ac.uk/inst/crd/crddatabases.htm#NHSEED was used to identify relevant 
manuscripts.  This has an international focus and includes studies of economic evaluations 
selected from a range of electronic databases (such as MEDLINE and EMBASE, Cochrane 
Library, PsychLit, Biomed Central) together with searching paper-based journals and other 
grey literature (e.g., working papers at centres of health economics research).  The NHS-EED 
reviews provide a structured abstract that separately considers the quality of the evidence of 
clinical effectiveness in addition to the economic evidence while providing an independent 
critical assessment of the study’s overall quality.  Medical databases were also searched due 
to the delay between the production of NHS-EED review abstracts and when the original 
research was published.   Reference lists of articles retrieved were hand-searched for 
additional relevant studies. Specific search terms, results, and reasons for exclusions are 
listed in Appendix 1.   
 
It is beyond the scope of this paper to discuss in detail the standard ‘best practice’ methods 
for economic evaluations, and the reader is referred to other quality resources on this topic.21, 
22    Briefly, good practice economic evaluations are transparent with respect to the policy 
question and perspective taken, adequate description of all comparators, detailed costing and 
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health benefit methods, incremental cost-effectiveness ratios (see Appendix 2) and detailed 
sensitivity analyses.  An incremental cost-effectiveness ratio provides information on the 
efficiency of one option compared to another by summarising its relative value for money.  
An average cost-effectiveness ratio is the same as an incremental cost-effectiveness ratio 
however it compares an intervention with baseline or zero (‘do nothing’) alternative. 23  
Ratios of up to US $50,000 (€36,767) per QALY gained would generally be considered 
economically attractive, although this is a crude and arbitrary benchmark.24  Sensitivity 
analyses test the stability of the incremental cost-effectiveness ratios by varying the point 
estimates used in the main analysis and are adequately justified (e.g. different effectiveness 
estimates from other epidemiological data, low and high confidence intervals, different 
possible costs or quantities of resources used).  These analyses are performed to deal with the 
uncertainty within the data estimates and intervention protocols that commonly occur in 
economic evaluations.  Relevant studies were critically appraised using the British Medical 
Journal’s 35-point checklist for reporting economic evaluations 
(http://bmj.bmjjournals.com/advice/checklists.shtml).25  Studies were categorised by 
behaviour type, tabulated according to key features and outcomes and synthesized using a 
narrative approach.  A narrative synthesis method was necessary because of the wide 
variability in economic study methods, outcomes and levels of quality, and because many 
economic evaluations include their own synthesis (meta-analyses) of epidemiological data for 
intervention efficacy and other data estimates.  In addition to presenting the key findings in 
their original local currency and price year, incremental cost-effectiveness ratios were 
converted to 2006 Euros (using inflation deflators for individual countries and purchasing 
power parities),26 where possible, to facilitate comparisons across studies.  We also present 
the time horizon for the economic evaluation, any assumptions on intervention compliance or 
relapse behaviours and any assumptions on long-term efficacy. 
 
Results  
 
Of the 586 articles identified, most were excluded because they were not one of the four 
behaviours, were not economic evaluations or they were only partial economic evaluations 
(e.g cost studies) (see Appendix 1). Two studies were discarded because they had been 
amended and re-published when follow-up data became available27, 28 and an additional two 
because later reports published outcomes in terms of QALYs gained.29, 30  This left a total of 
64 articles in the review.  For each behaviour type, the number of studies included: smoking 
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cessation (15), physical activity (13), alcohol (12) and nutrition (7).  An additional 17 
interventions simultaneously addressed more than one of these four behaviours and were 
categorised as ‘multiple behaviour interventions’ (see Tables 1-5).  
 
Smoking-cessation interventions 
 
Smoking-cessation strategies were comprised of counselling by a range of health 
professionals and with or without nicotine replacement therapy or bupropion, printed 
materials or telephone quit lines and targeted certain types of smokers: highly addicted, new 
smokers, pregnant women, relapsers and potential relapsers (Table 1).  The durations of the 
intervention ranged from 6-24 months while the economic analyses took a lifetime horizon.  
Despite the heterogeneity among the studies in terms of the target populations, intervention 
components, economic perspective and primary outcomes, the incremental cost-effectiveness 
ratios never exceeded €14,000 per QALY gained and €9,422 per LYS (2006 Euros), with the 
exception of one study that assessed Sudden Infant Death Syndrome deaths averted.31  
Studies reporting incremental cost per LYS ranged from €1,012 to €9,42232-38 (2006 Euros).  
Cost per quality-adjusted life years (QALYs) gained ranged from €2,737 to €13,909, 32-35, 37 
and cost per quitter up to €5,398 33(2006 Euros) with ranges depending on age and gender.  
Cost-effectiveness ratios were higher for interventions combining nicotine replacement 
therapy with counselling compared to counselling alone.  Unfortunately, in eight studies there 
was limited information reported on the quality, detail, justification or synthesis of estimates 
for the effectiveness of the interventions. 31-33, 35, 36, 39-41  Costs were of limited scope for two 
studies32, 35 or costing methods were inadequately reported for two studies.32, 40  Sensitivity 
analyses were incomplete in one study 42 and non-existent for two studies .31, 32  In one study 
43 costs were not discounted because of the short-time frame of the costing period (up to one 
year), however effects were discounted making the analysis inconsistent and against current 
recommendations.22  Other limitations were a failure to state the economic perspective for 
three studies, 31, 43, 44 no price year provided for one study,37 and inadequate descriptions of 
the interventions in one study.31    
 
(Insert Table 1 here) 
 
Alcohol interventions 
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Alcohol interventions were comprised of physician counselling techniques and aimed at 
either hospital patients, families or adolescents (Table 2). Using cost-benefit analyses where 
benefits were valued as reduced health care costs, averted motor vehicle accidents and 
criminal events/court case costs, results showed net benefits to society of €7,319 45 per patient 
and €9,334 46 (2006 Euros) per family.  Similarly, when benefits were valued in terms of 
costs saved from hospitalizations averted, trauma and emergency room services avoided, net 
cost savings were found of €3.84 47 and €10.67 48 to every €1 invested in the interventions.  
Incremental cost per QALY was €23,865 (2006 Euros) for a motivational therapy program 
compared to a behavioural therapy program,49 up to € 13,824 per QALYs for various 
intensities of alcohol therapies50 and up to €51,674 per LYS for a screening and intensive 
advice intervention compared with an intervention with lower intensity.51  Corry et al. (2004) 
found very high ICERs of €123,549 per year of life in disability averted for a current care 
option versus no treatment compared to €72,473 per year of life in disability averted for 
optimal care.52  Strengths of the research by Fleming et al. (2002) and UKATT (2005) 
evaluating family physician counselling programs were the diverse and large samples 
(n≈750), 4-year follow-up rates, randomized designs and intention-to-treat procedures.  Three 
studies reported average ratios, 45, 48, 53 two did not undertake sensitivity analyses, 48, 53 one 
study inadequately addressed issues of non-randomized samples or small samples, 48 and two 
others provided no price year54-56 making price conversions difficult. 
 
(Insert Table 2 here) 
 
Physical activity interventions 
 
Interventions included a range of targets (e.g., from moderate intensity of physical activity to 
vigorous exercise), delivery methods (e.g., health professional advice, group sessions and 
nurse-led home-based programs) and were aimed at a wide variety of target populations, 
including those with or without chronic illnesses (Table 3).    Incremental cost per LYS were 
in the range €1,845 to €47,515,57-59 and cost per QALY gained was €2,162 to €53,119 60-
64(2006 Euros).  Cost savings per incremental unit of improved physical activity scores were 
found in one study65 (2006 Euros).  Very small between-group differences, of questionable 
clinical importance, were found for one study assessing two rehabilitation programs for 
breast cancer compared to usual care.63  DeVries et al. (2002) found exercise training to be 
highly cost-effective when compared to two vascular surgeries for persons with coronary 
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artery disease.  From the employers perspective, and using cost-benefit analysis where 
benefits were measured in cost savings from reductions in sick leave payments, physical 
activity counselling produced net savings of €305 per participant over 9 months. 66  The 
analytical perspective used (i.e., service provider, society or consumer, etc.) was unclear for 
three studies,58, 67, 68 and often the quantity of resources used and costs were not reported 
separately.58, 61, 63 Overall, sensitivity analyses were adequately reported as were the methods 
for the estimation of costs and measures of effectiveness.  
 
(Insert Table 3 here) 
 
Diet interventions 
 
Counselling interventions with various health professionals were targeted at persons with 
diabetes or at high risk of developing diabetes,69, 70 heart disease/obesity, 71 overweight 
children72 or adults73 (Table 4).  Average costs per mg/dL change in fasting glucose levels 
were €5.04 for the dietitian program versus €6.64 for the basic care program (2006 Euros).69  
In another evaluation 72, average costs per ‘% decrease in energy from fat’ over 12 months 
were €161 for a parent/child intervention versus €101 for counselling  (2006 Euros).    Tsai et 
al. (2005) found a low carbohydrate dietary intervention was dominant over a standard diet, 
but the differences in costs and in QALYs across the two options were not statistically 
significant.74 For a dietitian counselling plus multidisciplinary care intervention, the 
incremental cost per patient achieving glycemic control was €3,705 (2006 Euros).70  
Counselling by a family practitioner was more cost-effective than a dietitian, with an 
incremental cost-effective ratio of €1,199 versus €8,757 per LYS respectively,71 and involved 
very small gains in terms of LYS (i.e., 14-22 days).  Better health outcomes were found if a 
family physician was the sole provider71 or aided a dietitian with nutrition counselling 
however costs were also higher.71, 73  Sensitivity analyses were not undertaken or were weak 
69, 72, 73, 75, costs were inadequately reported70, 73 and with one exception,74 all studies had 
short time-frames (1 or 2 years) with no attempt to estimate longer-term costs and outcomes. 
 
(insert Table 4) 
 
Multiple behaviour interventions 
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Multiple behaviour or lifestyle interventions included different combinations of behaviour 
modification with or without health checks, pharmacotherapies, surgeries to improve health 
behaviours in general populations76-80 or those with common chronic diseases (Table 5).  
Most multiple behaviour studies employed risk factor modelling techniques to estimate 
survival outcomes, and many used Markov or simulation modelling 79-84 to address 
uncertainty of evaluation estimates (Table 5).  With one exception,78  incremental cost per 
LYS ranged from €3,274 to €64,92176-79, 85(2006 Euros).   Incremental cost per QALYs 
ranged from cost savings to €24,523 (2006 Euros),80-82, 84, 86 excluding two studies with 
extreme incremental cost per QALYs of €206,24178 and €203,19781 (2006 Euros).  These 
very high ICERs were driven by very small differences in QALYs across the intervention 
options.  Salkeld et al. (1997) reported that if their GP-delivered lifestyle intervention was 
targeted at high-risk men, the incremental cost-effective ratios were €53,569 per LYS and 
€40,094 per QALY gained (2006 Euros) compared to routine care. Four studies were found 
to have weak or no sensitivity analysis 78, 87-89 and two studies lacked sufficient detail on 
costing methods.78, 90  Generally, authors presented little or no information on the quality, 
structure or validity of the economic models used.  Interventions aimed at men were more 
cost-effective than those for women in two studies.76, 78  One study performed a cost-benefit 
analysis of a school-based obesity program measuring benefits as reduced costs for medical 
and productivity costs avoided and found, with 80% probability, net savings to society. 
 
(Insert Table 5 here) 
 
Discussion  
 
To our knowledge, this is the first review of the growing cost-effectiveness literature on face-
to-face health behaviour interventions targeting smoking, physical inactivity, poor diet and 
alcohol misuse. Consistent with previous reports 12, 13, 15, 57 and subject to the limitations 
identified above, economic evaluations for smoking-cessation were found to be excellent 
public health investments and show economically attractive findings (i.e., € 14,000 per 
QALY gained, 2006 Euros).  For the evaluations of alcohol interventions, net cost savings to 
society were found in four studies, favourable cost-effectiveness ratios (<€ 23,865 per QALY 
gained) in two others and one study demonstrated relatively high cost-effectiveness ratios (€ 
72,473 per year of life in disability averted for optimal care versus no treatment.  The 
findings for physical activity interventions generally indicated favourable cost-effectiveness 
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(<€ 53,119 per QALY gained) and two studies showed net cost savings.  For the dietary 
interventions, incremental cost-effectiveness ratios (ICERs) were not produced for three of 
the seven studies and different outcome measures made any conclusions difficult.  However, 
one study showed cost-effective findings  of € 8,757 per LYS.   
 
Incremental cost per QALY ratios for multiple behaviour interventions targeting high-risk 
populations ranged from cost saving to € 40,094 (2006 Euros). They were mostly cost-
effective and higher than for smoking cessation interventions alone.  No study explicitly 
addressed the possibility that multiple behaviour interventions may produce greater 
efficiencies compared to single behaviour interventions.  While many individuals engage in a 
range of risk factor behaviours,91 multiple behavioural interventions or ‘lifestyle’ 
interventions may be the logical way forward, since they are risk factors for most chronic 
diseases.  They also interact with each other throughout the lifecycle 92  and increase overall 
absolute risk for chronic diseases.  Behaviour management play a crucial role in primary and 
secondary prevention of chronic disease. Other treatment strategies that aim to modify single 
risk factors are found to have incremental cost-effectiveness ratios over € 85,000 per life-year 
saved, including some hyperglycemic drugs to lower blood glucose (pioglitazone and 
nateglinide),16 antihypertensive drugs (calcium channel blockers, antiadrenergics),17 and 
cholesterol-lowering drugs (colestipol, cholestyramine).17   
 
Overall, the behavioural interventions aimed at populations with high-risk factors for disease 
were more cost-effective than those aimed at healthy individuals due to the larger health 
gains produced in these targeted cohorts.  For example, middle-aged men often engage in 
multiple poor behaviours,91 are set to gain more when they change to healthy lifestyles, which 
produces lower incremental cost-effectiveness ratios compared to other cohorts.93  Due to the 
limited number of studies involving lower socioeconomic subgroups, known to have poorer 
health behaviours, further work is needed to determine the economic findings attributable to 
disadvantaged populations and the related issue of equity in resource distribution.   This issue 
is especially important when translating an intervention into a different setting.  
 
Generally, the costs of the behavioural interventions reviewed were low relative to those for 
other health care interventions such as pharmaceutical management. Interventions were 
primarily of a counselling nature, low-technological, community-based and did not require 
extensive capital outlays.  Despite this, many studies in this review also showed that 
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behavioural interventions alone had lower effectiveness (e.g., counselling alone for smoking 
cessation had lower effectiveness than when combined with NRT), and it is the overall cost-
effectiveness ratios that are important rather than simply assessing costs.  With the exception 
of some interventions with longer follow-up contacts, the interventions were also short-term 
and, unlike other health interventions (e.g., pharmaceuticals) where resources are required for 
the remainder of an individual’s life, total lifetime expenditure was small.  However, costs of 
human resources in community-based health providers should not be trivialized, as these 
organizations may find that operational costs (in terms of staff training, adequate salaries to 
promote staff retention, time and space to implement interventions, etc.) are relatively high.  
Few studies in the review included indirect costs such as potential cost-savings due to better 
health and lower use of health services or future health care costs associated with living 
longer. 
 
An important part of cost-effectiveness analyses of behavioural interventions is establishing 
the link between behaviour change and long-term mortality and quality of life outcomes.  The 
studies here have drawn on both trial evidence and epidemiological data to support these 
links, however relatively weak evidence is available for the long-term health effects of 
physical activity, diet and drinking compared to smoking cessation.94  Economic outcomes 
here for alcohol, diet and physical activity interventions are generated over the short term, 
aligning to the intervention follow-up times, and do not attempt to predict longer term 
effectiveness or maintenance of healthy behaviours.  Despite being non-invasive and having 
minimal risk of adverse events, intervention effects are usually small across time and across 
treatment options (e.g., 5% smoking-cessation rates at 12 months is considered clinically 
meaningful although this small gain translates to relatively high numbers of life years saved). 
This is a reflection of the difficulty in modifying health behaviours in populations, including 
persons with confirmed risk factors for chronic disease and also by the ‘natural’ health gains 
occurring in the comparison groups (e.g., unaided smoking quit rate, physical activity 
improvements in ‘usual care’ groups).   New epidemiological data is constantly emerging to 
challenge cost-effectiveness outcomes, despite the conservative health effect estimates often 
used and the use of sensitivity analyses.  For example, Yudkin et al. (2003) reported a 7-year 
smoking relapse of 54%, with the studies in this review using estimates ranging from 0% to 
40%, 29, 32, 37, 38, 40, 41, 95 because of this, underestimated cost-effectiveness ratios were 
produced. 
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When comparing these cost-effectiveness results across studies, particular care should be 
taken to acknowledge the different methods used, the different cost types, outcomes and 
baselines.  Hence, a simple comparison of ICERs should be avoided.  Generalizing the results 
of many or any one study from this review will require economic re-analysis to reflect local 
conditions, particularly as the evidence-base for the effectiveness of the interventions is 
constantly changing. Issues contributing to the generalisability and variation in cost-
effectiveness ratios reported here include differences in: health care systems, incentives to 
health care professionals and institutions, clinical practice, population demographics, 
population values, target populations, risk factor profiles, disease prevalence, currency 
purchasing powers and the availability of and access to new technologies 96 (see Cornuz et al. 
[2006] for a recent multi-national comparison on pharmacotherapies for smoking 
cessation).93  The decision to implement a program will also involve ethical and political 
considerations, and issues such as equity, reach, needs and priorities.  Through this process, 
the program with the lower cost-effectiveness ratio may not always be the best one (see Bala 
& Zarkin 2002 for a further discussion).97 The studies in this review typically omit cultural 
minorities and disadvantaged populations known to have increased levels of high-risk 
behaviours.98   However, serving these disadvantaged populations may involve higher costs 
required to reach these sub-groups and more intensive interventions to maintain behavioural 
change.99  Finally, the mix of strategies to control for many chronic diseases in practice may 
be more complex than those described in the studies here.  They may use multiple methods 
(pharmacotherapy, behavioural therapy and surgery) and therefore additive effects and 
additional costs may need to be considered.   
 
Study limitations and strengths 
Retrieval of all possible papers was limited to those referenced in medical databases and 
excludes those located in the grey literature (outside that performed by NHS-EED) and those 
produced in monographs and books.  All papers published after 1995 in English-language 
journals were included.  A quality grading system was not employed because none are 
extensively used or widely validated,100, 101 and there are limitations with using such a 
system, as important information may be missed in the reduction and categorisation process. 
101  However, a comprehensive checklist was used to establish the methodological quality 
and/or reporting of methods in an explicit and standardized way and revealed a number of 
methodological limitations.  The overall quality of the economic evaluations varied widely 
across and within each behaviour category. 
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This review targets clinicians, behavioural scientists, and public health researchers.  The 
information will be most useful for decision-makers wanting to know which interventions are 
the ‘best buys’, when making investments in preventive public health.  A study of interest 
may be identified as appropriate for a particular setting and, following some re-analysis to 
reflect local conditions, the intervention may be considered by policy makers for translation 
into practice.  The review may also act as a reference guide for behavioural interventions 
tested elsewhere and the relative differences of the interventions compared using a common 
currency.   In addition, the review has highlighted the gaps in economic evaluation methods 
and steers researchers and evaluators towards improving their practice and reporting high-
quality economic findings, whilst building on existing knowledge. 
 
Conclusion 
 
Wide-scale implementation of health behaviour interventions to curb the growing chronic 
disease burden in developed nations is an important population health objective.  This review 
provides the current state of evidence for economic evaluations in 64 studies across the four 
key behaviours of smoking, alcohol, diet and physical activity.  There was wide variation in 
terms of sample populations, interventions, settings, and intervention outcomes, in addition to 
the use of varying economic methods.  Similarly, the quality of the studies in the review was 
wide-ranging, with many studies having major limitations when evaluated against a 
comprehensive economic evaluation checklist.   Nevertheless, overall most health behaviour 
interventions were very good value on economic grounds, especially smoking-cessation 
counselling with pharmacotherapies and interventions targeting high-risk populations.  
Further economic evaluations of stronger quality are necessary to establish the cost-
effectiveness of interventions for diet, alcohol and physical activity.  Care is needed when 
generalising these findings in local settings, and economic re-analysis is recommended to 
account for different disease prevalence, health care systems (prices and access to health 
care) and currency purchasing powers.  Further evaluations should target multiple behaviour 
interventions due to the potential synergy to be gained.  Markov modelling and Monte Carlo 
simulation approaches (and their quality assessment) will be inevitable in future 
investigations of behaviour change interventions, because of the complexity of treatment 
effects, multiple behaviour interactions and the lifelong time-frame advocated for both 
lifestyle improvements and cost-effectiveness analysis.   
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Appendix 1. Summary of search results 
 
Limits: 1995-2005, terms in title or abstract, original research 
 
Search terms – combination of: Hits Not 
behaviour 
change or 
not 4 
behaviours 
Not 
CVD, 
obesity, 
diabetes, 
cancer 
Not 
face-to-
face 
intvns 
Not econ 
evaluations 
or partial 
evaluation 
Not 
person 
level 
behaviour
intvns 
Non-
English 
No C/E 
ratios 
Insufficient 
data to 
assess econ 
evaluation 
Already 
included 
Final1 
Cost, cost-effectiveness, cost-benefit, 
cost-utility and smok* 
64 1 0 3 16 16 1 0 1 11 15 
Cost, cost-effectiveness, cost-benefit, 
cost-utility and physical activity, 
exercise, fitness 
146 59 3 1 17 7 0 1 17 27 14 
Cost, cost-effectiveness, cost-benefit, 
cost-utility and diet*, nutrition, obesity, 
weight loss 
165 107 4 3 15 6 1 4 0 12 13 
Cost, cost-effectiveness, cost-benefit, 
cost-utility and alcohol, drink* 
85 29 1 1 28 7 0 7 0 5 7 
Cost, cost-effectiveness, cost-benefit, 
cost-utility and behavio(u)r,  lifestyle, 
risk factor  
126 51 9 8 16 0 1 1 2 19 19 
 
1. A further two studies were discarded because they had been amended and re-published when follow-up data became available27, 28 and an additional two because later reports published 
outcomes in terms of QALYs gained 29, 30 
 
 
 17
Appendix 2 Definition of an incremental cost-effectiveness ratio (ICER) 
 
An incremental cost-effectiveness ratio is defined by: 
 
E
C
EE
CC
ICER
CI
CI
Δ
Δ=−
−=  
 
where: IC  represents a measure of economic costs after the intervention has been 
implemented; CC represents a measure of economic costs with the comparator (i.e. usual care 
or some other intervention); IE represents the level of health benefits after the intervention 
has been implemented; and, CE  represents the level of health benefits with the comparator. 
Therefore, CΔ  represents the change in cost due to the intervention compared with the 
comparator and EΔ represents the change in health benefits due to the intervention compared 
with the comparator.  The ratio of CΔ  and EΔ is interpreted as the amount by which cost 
changes in order to obtain a unit of health effect and this is the incremental cost-effectiveness 
ratio (ICER).  An average cost-effectiveness ratio is calculated by dividing program costs by 
the change in outcomes generated by the program.  This is defined as the additional outcome 
achieved by a program compared to a baseline of doing ‘nothing’23
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Table 1 Summary of key features of cost-effective evaluations for smoking-cessation interventions 
 
First Author 
& Year 
Interventions Assumptions regarding 
compliance 
Viewpoint Price 
Year 
Key findings Converted ICERs to 
2006 Euros 
Fiscella 199635 
 
Counselling + nicotine 
patch vs counselling  
Quit rate 4-7.9%, natural 
quit rate 2.5%, relapse rate 
10-50%, future quit rate 1-
4% 
Consumer 1995 US$4,390 -$10,943 per QALY (women) 
US$4,955 -$6,983 per QALY (men) 
variation depends on age,  
sensitive to quit rates & discount rate 
Up to €12,449 per QALY 
gained 
Lowin 199644 Counselling + patch vs 
counselling vs no 
intervention 
Not stated Not stated ? 
provider 
1995 £1,742-4,258 per LYS (patch + counselling 
vs no intvn) variation depends on 
men/women and age,  
£1,846 per quitter vs counselling,  
lowest ICER for men aged 45-55 years  
Up to €5,996 per LYS 
Mudde 199642 Self-help vs group based 
intvn 
Quit rate 12-23% Provider, 
consumer, 
society 
1990 1US$648 - $1,297 per quitter,  
variation depends on number of quitters 
No ICER provided 
Wasley 199743 Counselling  + nicotine 
patch vs counselling 
Quit rate 4.5-17.6%, 
natural quit rate 1%, 
relapse rate after 1 year 
35% 
Not stated  
? Consumer, 
provider 
1995 US$1,796-$2,949 per LYS (men) 
US$3,040-$4,391 per LYS (women) 
variation depends on age 
Up to €4,996 per LYS 
Meenan 
199839 
Counselling + education + 
follow up vs usual care 
Incremental quit rate 0.6-
0.8% 
Hospital 1994 US$1,691-$7,444 per LYS, 
variation depends on discount and quit rates 
For 500 smokers $175-$770 per LYS 
Up to €8,708 per LYS 
Crealey 199838 
 
Pharmacy-based program 
vs no intervention 
Quit rate 5-25%, relapse 
rate 0-15%, natural quit 
rate 0-2% 
Service 
provider 
1997 £197 - £351 per LYS (men) 
£181 - £772 per LYS (women),  
sensitive to success rates,  
lowest ICER for men aged 50-65 years 
Up to €1,029 per LYS 
Stapleton 
199941 
 
GP counselling +booklet + 
NRT vs counselling 
Quit rate 2.8-11.3%, 
relapse rate after 1 year 
30-50%, natural quite rate 
1.2-1.8% 
Health 
system 
1998 £345 - £785 per LYS, 
variation depends on age group,  
lowest ICER for 35-44 years  
Up to €1,012 per LYS 
Cromwell 
200133 
15 smoking cessation 
strategies recommended 
by US guidelines 
Quit rate 5.6-21.6%, 
relapse rate 35-55%, 
natural quit rate 5% 
Society 1995 US$1,171 - $2,406 per QALY,  
Lowest ICER for counseling + nicotine 
patch  
US$2,310-$4,745 per quitter  
Up to €2,737 per QALY 
gained 
Up to €5,398 per quitter 
Pollack 200131 
 
Smoking cessation for 
pregnant women vs control 
Quit rate 15% Not stated 
?health 
1998 US$210,500 per SIDS death averted €223,899 per SIDS death 
averted 
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system 
Tran 200295 Pharmacy advice ± cold 
turkey, patches, gum, 
bupropion vs no intvn 
Quit rate 15-40% Consumer Not 
stated 
Cost per quitter vs no intvn: US$236 cold 
turkey, $936 patch, $1,232 gum $1,150 
bupropion, US$720-1,418 per LYS, 
US$450-578 per QALY 
Conversion not possible 
Song 200240 NRT vs bupropion vs GP 
advice 
Quit rate 3-12%, natural 
quit rate 0.5-2%, relapse 
rate 30-40% 
Health 
service 
2001 US$1,441-$3,455 per LYS NRT vs advice, 
$920-$2,150 bupropion + advice per LYS, 
$1,282-$2,836 per LYS NRT + bupropion + 
advice  
Up to €3,374 per LYS 
Chirikos 
200432 
Different combinations of 
high/low contact with 
high/low content to 
prevent relapse vs NRT± 
intensive counselling  
Relapse rate 0%, relapse 
rate at 2 yrs 34-42% 
Consumers 2000 Relapse intvn US$2,400 - $4,300 per 
QALY, US$5,000-$9,100 per QALY 
excludes natural quitters,  
$488 mean cost to patient to quit 
Up to €9,162 per QALY 
gained 
Javitz 200437 
 
Different combinations of 
bupropion doses and 
counselling 
Quit rate 7.9-14%, relapse 
rate 0-37%, natural quit 
rate 0-2.5% 
Not stated 
?Service 
provider 
Not 
stated 
  
$US528-$2,194 per LYS,  
$US512-$1,796 per QALY,  
lowest ICERs for men aged 30-65 years, 
sensitive to discount and quit rates 
Conversion not possible 
Gilbert 200436 Pharmacotherapies + 
counselling vs counselling 
only 
Quit rate counselling OR 
1.73, natural quit rate 
2.5%, relapse rate 35% 
after 1 year 
Health 
service 
2002 $US 1,311-$6,032 LYS (men)  
$2,052-$9,777 (women),  
lowest ICERs for men aged 35-49 years 
Up to € 9,422 per LYS 
Feenstra 
200534 
5 intvns – minimal contact, 
counselling + NRT, 
intensive counselling ± 
bupropion, telephone 
counselling vs current 
practice (mix of above) 
Quit rate 3.4-17.2% Societal 2000 €1,600 - €10,500 per QALY,  
counseling with bupropion more C/E than 
intensive counseling with NRT 
€13,909 per QALY 
gained 
 
Abbreviations:  C/E – cost-effectiveness, GP – general practitioner, ICER – incremental cost-effectiveness ratio, LYS – life years saved, intvn – intervention, NRT – nicotine 
replacement therapy, QALY – quality-adjusted life-year, SIDS – Sudden Infant Death Syndrome. 
 
1. Average cost-effectiveness ratios reported only
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Table 2  Summary of key features of cost-effective evaluations for alcohol abuse interventions  
 
First 
Author & 
Year 
Interventions Time 
horizon 
Viewpoint Price 
Year 
Key findings Converted ICERs to 
2006 Euros 
Downs 
199556 
Screening +counselling high-risk 
taking adolescents vs no program 
5 years Society Not 
stated 
US$10,000-12,000 per LYS @ 5% 
efficacy, marginal costs of adverse events 
prevented $4,580 
No conversion possible 
O’Farrell   
199648 
Behavioural marital therapy ± 
alcohol counselling vs individual 
counselling 
2 years Society 1992 1Benefit to cost ratios: 
counselling+marital  vs individual 
counselling $8.64 for every $1 invested  
Average cost per continuously abstinent 
rate: US$2,143 counselling + marital, 
$3,580 interaction couples counselling  
€10.67 saved for every €1 
invested  
Lindholm 
199851 
Screening and advice to people 
with alcohol problems – two 
different program intensities 
Lifetime Not stated  
?Health provider 
1997 <€44,000 per LYS in more intensive 
intervention,  
lower ICER for nurse-led rather than GP 
€ 51,674 per LYS 
Pettinati  
199953 
Inpatient vs outpatient treatment 
based on multimodal 12-step 
program  
3 months Not stated 
?Consumer 
Not 
stated  
1 US$9,014  for 3 month inpatient vs 
outpatient  
US$1,420 per probability of return to 
drinking 
No ICER provided 
Weisner 
200055 
Day hospital vs outpatient program 
for alcohol and drug dependence 
8 months 
after 
program 
Provider  Not 
stated 
US$9,576 per drug and alcohol 
abstinence (self-selected group),  
US$5,464 per alcohol abstinence for day 
hospital vs outpatient program 
No conversion possible 
Fleming 
200246 
Long-term GP advice vs booklet  4 years Health system & 
society 
1993 Health system net benefit US$546 per pt 
(95%CI $71, $1164) 
Societal net benefit US$7,780 per pt 
(95%CI $894, $14,668) 
€9,334 net benefit per 
patient to society 
Spoth 
200245 
 
Two youth alcohol-prevention in 
young adults – 7 session vs 5-
session family programs 
4 years Society 1992 1US $12,459 per prevented case (7 
session intvn) and $20,439 per prevented 
case with 5 session intvn, Net benefit 
$5,923 and $2,697 per family, $9.60 
saved for every $1 invested or $5.85 – 
both programs cost-beneficial.  
€7,319 net benefit per family 
to society 
Corry 
200452 
Current care vs optimal care vs no 
treatment 
1 year Government 1997 Compared to no treatment, current care 
AU$98,095 and optimal care AU$57,542 
per years of life in disability averted. 
€ 123,549 per years of life in 
disability averted 
€ 72,473 per years of life in 
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disability averted 
UKATT 
200549 
 
Social behaviour vs motivational 
enhancement therapies 
1 year Provider + public 
sector 
2001 £18,230 / QALY for motivational relative 
to social behaviour therapies, social 
therapy dominates  
If WTP £30,000 motivation therapy 58% 
probability of being C/E vs social therapy 
€ 23,865 per QALY gained 
Fals-
Stewart 
200554 
Brief cognitive behavioural therapy 
vs standard CBT vs individual-
based therapy vs 
psychoeducational therapy for 
couples 
1 year Society Not 
stated 
Average C/E for every $100 spent on 
brief CBT.  Brief CBT as efficacious as 
standard CBT 4.61 vs 3.30 
No conversion possible 
Genitello 
200547 
Alcohol screening and intervention 
vs none in trauma patients 
attending an emergency department 
1 year Health provider 2000 US $43.81 saved for every $ 1 spent on 
intervention, cost saving $89 per injured 
adult, 91.5% probability findings are C/E 
€ 3.84 saved for every € 1 
invested.  
 €77 saved per injured adult. 
Mortimer 
2005102 
Brief intvn vs psychotherapy vs 
drug therapy for problem and 
dependent drinkers vs usual care 
Lifetime Society 2003 AUD $490-$12,966 per QALY, higher 
for more intensive intvn and very 
dependent drinkers 
€ 13,824 per QALY 
 
Abbreviations:  C/E – cost-effectiveness, GP – general practitioner, ICER – incremental cost-effectiveness ratio, LYS – life years saved, intvn – intervention, QALY – 
quality-adjusted life year, CBT – cognitive behavioural therapy. 
1. Average cost-effectiveness ratios reported only
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Table 3 Summary of key features of cost-effective evaluations for physical activity interventions 
 
First Author 
& Year 
Interventions Time horizon & 
assumptions 
Viewpoint Price 
Year 
Key findings Converted ICERs to 
2006 Euros 
Ades 199757 Cardiac rehabilitation 
exercise vs no intervention 
Lifetime 
modelling, 
assumed no 
difference in 
benefit after 3 
yrs 
Consumer 1995 US $2,130 per LYS (1985)  
US $4,950 per LYS (1995) 
€ 5,631 per LYS 
Stevens 199868 Exercise intvn for 45-74 yr 
olds vs minimal written 
materials  
8 months Not stated  
?Service provider 
Not 
stated 
?1997 
1£623 per % decrease in sedentary 
persons, £2,498 per inc persons active, 
£327 per change of person to higher 
exercise level  
No ICER provided 
Sevick 200067  Compares exercise lifestyle 
intvn vs structured 
behavioural skills in 
sedentary adults Project 
ACTIVE 
2 years Service provider 
and  consumer 
Not 
stated 
?1994 
1$US 343 per mth per additional kg lost at 
2 years, Total costs were $49,805 for 
lifestyle intvn vs $134,411 structured 
intvn 
No conversion possible 
Lowensteyn   
200059 
Supervised vs unsupervised 
exercise program for 
cardiovascular disease 
(CVD) 
Lifetime 
modelling, 
compliance  
20-50% 
Service provider 1996 <US$12,000 / LYS all pts, <$15,000 per 
LYS men (CVD), $12,000-$43,000 
women (CVD) and men (no CVD), basic 
unsupervised intvn highly C/E all groups 
Up to € 47,515 per LYS 
Georgiou  
200158 
Exercise training for 
chronic heart failure vs no 
intervention 
14 months, after 
follow-up 
survival identical 
across groups 
Not stated  
?Society 
1999 US$1,773 per LYS, included medically 
stable heart failure male pts only 55-64 
yrs, omitted some societal costs 
€ 1,845 per LYS 
deVries 200262 Combinations of walking 
exercise ± vascular surgery  
Lifetime 
modelling 
Society 1995 US$38,000 per QALY gained PTA/EX 
(vs EX only) US$311,000 per QALY 
gained EX±PTA/bypass (vs PTA/EX) 
Surgeries high risk and expensive. 
€ 43,230 per QALY 
gained PTA/EX vs EX 
Treesak 
200465 
Supervised exercise vs 
lower extremity PTA vs no 
intervention 
1 year 
Weekly 
compliance rate 
0.89 for 3 
months 
Society 2001 Exercise therapy at 6 months cost-saving 
compared to PTA.  Cost per increase in 
walking ability. Exercise therapy 
clinically efficacious and cost-effective  
€ cost-saving 
Munro 200464 
 
Exercise intvn for 65+yrs vs 
control 
Low adherence, 
similar survival 
Service provider 1994 €17,174 per QALY (95%CI €8,300-
87,120), 2 year time frame 
€ 29,310 per QALY 
gained 
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across groups 
Yu 200490 Cardiac rehabilitation with 
exercise vs no intervention 
Life expectancy 
same in 2 groups 
Health system 2003 US-$650 (saving) per QALY  per patient, 
n=181 in cardiac rehabilitation, cost-
saving, 2 year follow-up 
-€612 (saving) per QALY 
gained 
Proper 
2004103 
Physical activity counselling 
at a work site vs no intvn 
9 months Employers Not 
stated 
€ 305 net costs gained from intvn, 
benefits in terms of costs of reduced sick 
leave payments 
Conversion not possible 
Briffa 200550 Exercise-based cardiac 
rehabilitation vs usual care 
1 year Health system 1998 AUD $42,535 per QALY – sensitive to 
utility scores 
€ 53,119 per QALY 
Gordon 
200563 
Physical therapy + support 
at home vs group exercise + 
psychosocial support vs no 
intervention for women with 
breast cancer 
1 year Society 2004 A$1,344 per QALY physical therapy 
intvn vs A$14,478 per QALY group 
exercise + support, modest difference in 
effects 
At WTP $14,400 50% probability that 
both interventions are C/E 
Up to € 13,235 per QALY 
gained 
Dalziel 
200661 
 
GP intervention  vs usual 
care 
1 year  
Survival rates 
0.59-0.71 
relative risk, 
active vs inactive 
Health system 2001 NZ$2,053 per QALY ($827 - $37,516) 
90% of ICERs < $7,500,  behaviour 
maintenance questionable but estimates 
conservative 
€ 2,162 per QALY gained 
 
Abbreviations:  C/E – cost-effectiveness, CI – confidence interval, CVD – cardiovascular disease, EX – exercise, GP – general practitioner, intvn – intervention, ICER – 
incremental cost-effectiveness ratio, LYS – life years saved, PTA – percutaneous transluminal angioplasty, QALY – quality-adjusted life year, WTP – willingness to pay. 
 
1. Average cost-effectiveness ratios reported only
 24 
Table 4  Summary of key features of cost-effective evaluations for dietary interventions  
 
First Author 
& Year 
Interventions Time horizon Viewpoint Price 
Year 
Key findings Converted ICERs to 
2006 Euros 
Franz 199569 Dietitian best practice advice 
vs basic care for diabetics 
6 months Health system 1993 1US$5.32 /mg/dL change in fasting 
glucose level vs $4.20 best practice, 
no stat. sign.  
No ICER provided 
Brannon 
199772 
 
Parent/child diet program vs 
dietitian for children 
1 year Patient/ family 1992 1Parent/child US$130 per % decrease 
fat vs counselling $82 – 12 months, 
Parent/child $36/mg/dL plasma low 
density lipoprotein vs counselling 
$30 
No ICER provided 
Glasgow 
199775 
Brief GP intervention vs usual 
care 
1 year Health provider Not 
stated 
$62 vs $105 per 1% reduction in diet 
and saturated fat intake, respectively. 
Increase cost per unit decrease in 
cholesterol (mg/dL) $8. 
No conversion possible 
Pritchard 
199973 
GP + dietitian counselling vs 
GP vs no intervention 
1 year Health system 1994 AUD$9.76 per extra kg lost for 
GP/dietitian group, $7.30 per extra 
kg lost dietitian only, better outcomes 
if GP involved 
€14 per extra kg lost GP+ 
dietitian  
Yokoyama   
200270 
Dietitian counselling + 
education + multidisciplinary 
care vs usual care  
2 years Health insurer 2000 US$3,680 per patient achieving 
glycaemic control  
€3,705 per patient achieving 
glycaemic control 
Olsen 200571 GP + dietitian counselling vs 
no intvn for pts with ischemic 
heart disease 
Lifetime 
1 year LYS 
assumed for 
lifetime 
maintenance 
Health system 2001 GP DKK8,213 per LYS, dietitian 
DKK59,987 per LYS, gains modest 
i.e. 14-44 days gained,  
If WTP 25,000 DKK per LYS, GP 
intervention acceptable only 
GP € 1,199 per LYS 
Dietitian € 8,757 per LYS 
Tsai 200574 
 
Low carbohydrate vs standard 
diet 
1 year, no 
differences in 
effects after 1 
year 
Society 2001 US -$1,225 per QALY (low carb diet 
dominant) but costs and QALYs not 
statistically different, wide 95%CIs 
and ICER spans 1 (weak result). 
Cost saving per QALY 
gained (low carb diet 
dominant) 
 
Abbreviations:  AUD – Australian dollar, C/E – cost-effectiveness, DKK – Danish krone, intvn – intervention, GP – general practitioner,  ICER – incremental cost-
effectiveness ratio. LYS – life years saved, QALY – quality-adjusted life year. 
 
1. Average cost-effectiveness ratios reported only
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 Table 5.  Summary of key features of cost-effective evaluations for multiple behaviour interventions 
 
First Author & 
Year 
Interventions Modelling 
approach  
Viewpoint Price 
Year 
Key findings Converted ICERs to 
2006 Euros 
Johannesson   
1995104 
Multiple behaviour intvn vs 
pharmacotherapy for 
hypertensive pts 
Framingham 
coronary heart 
disease model 
Society 1991 62,000 – 163,000 SEK per LYS 
depending on different estimates of 
risk factors, highly sensitive to 
assumptions about quality of life 
during treatment 
Up to € 22,034 per LYS 
Field 199576  Health checks + counselling 
± pharmacotherapy 
Framingham 
coronary heart 
disease model 
National Health 
Service 
Not 
stated 
?1993 
?£1,240 - £2,180 per LYS depending 
on basic to comprehensive intvn, 
more cost-effective in men and those 
higher in age. 
Conversion not possible 
Oldenburg 
1995105 
Health risk assessment vs 
risk factor education vs 
behavioural counselling vs 
behavioural counselling+ 
incentives 
- Health system Not 
stated 
Behavioural counselling more C/E 
than risk factor education at 
maintenance phase (1 year) 
Conversion not possible 
Lindholm   
1996106 
 
Community health 
promotion activities to 
prevent CVD 
- Health system, 
societal 
1992 1 Societal £1200 per LYS (range 
£14,900 to net savings) 
Health system £1100 to £4050 
No ICER provided 
Johannesson 
199685 
Usual vs intensive 
counselling with or w/o 
pharmacotherapy in high-
risk CVD population 
CVD risk 
factor 
modelling 
Health system 1991 US $51,000 usual advice + drug vs 
intensive treatment.  Intensive 
treatment is not C/E – dominated. 
€ 64,921 per LYS 
Salkeld 199778 GP lifestyle intvn for 
cardiovascular disease vs 
routine care 
Simulation 
model 
Govt health 
provider 
1994 AUD$191,689 per LYS,  $152,128 
per QALYs (men),  sensitive to 
behaviour change through time, 
$29,574 per QALY high risk men, 
small benefits found 
€259,874 per LYS, €206,241 per 
QALY gained (men) 
€53,469 per LYS, €40,094 per 
QALY gained (high risk men) 
Segal 199879 Six programs for diabetes – 
surgery, group behaviour, 
media campaign, GP advice, 
intensive diet and behaviour 
program vs no intvn 
Markov 
modelling, 
Success rates 
10-50% 
Health system 1997 Behavioural/diet programs for high 
risk groups highly C/E relative to 
other programs AUD$1000-$2600 
per LYS, surgery poorest option, 
exploratory analysis 
Up to €3,274 per LYS 
Wylie-Rosett 
200188 
Weight loss intervention – 
minimal, intermediate and 
intensive levels 
- Health provider Not 
stated 
?1997 
1US $ 6.32 , $8.57, $18.78 per pound 
of weight lost for minimal, 
intermediate, intensive levels 
No ICER provided 
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Finkelstein  
200287 
Cardiovascular disease 
screening with enhanced vs 
minimal lifestyle intvn 
(WISEWOMAN project for 
financially vulnerable) 
Coronary heart 
disease risk 
factor model  
Not stated 
?Service provider 
Not 
stated 
?1996 
US$637 for % point decrease in 10-
year probability of coronary heart 
disease (enhanced over minimal 
program) , reductions in two 
programs not statistically significant. 
Conversion not possible 
Yosefy 200389 Diet, exercise, smoking-
cessation, pharmacotherapy 
for hypertension 
- Not stated  
?Service provider 
2002 1US$506 per LYS , program needs to 
run for 10 years for positive C/E 
results (savings), little synthesis of 
costs and effects. 
No ICER provided 
Lindgren 200377 Combinations of exercise + 
diet advice + no intervention 
Framingham 
coronary heart 
disease model 
Society + Health 
system 
2000 127,065 SEK per LYS dietary vs 
control, if declining effect of intvn 
assumed, diet most C/E option  
€ 15,375 per LYS 
Wang 200380 School-based obesity 
program vs no intvn 
25 year 
decisional 
model 
Society 1996 $US 4,305 per QALY gained, 95% 
CI $1,615-9,010, cost savings 
$7,313, 80% probability 
€ 4,757 per QALY gained 
 
€ 8,801 net cost savings 
Warren 200486 Pharmacotherapy + diet + 
lifestyle advice vs advice 
only 
Framingham 
coronary heart 
disease model 
National Health 
Service 
2000 £4,870 per QALY for Sibutramine + 
lifestyle vs lifestyle alone 
€ 6,005 per QALY gained 
Herman 200582 Lifestyle modification vs 
pharmacotherapy vs placebo 
for adults at risk for diabetes 
Markov 
modelling 
Health system & 
societal 
2000 US$1,124 per QALY lifestyle vs 
placebo 
$31,286 per QALY medication  vs 
placebo 
Lifestyle dominant 
€ 1,132 per QALY gained 
Raftery 200584 
 
Nurse-led clinic lifestyle vs 
medical care 
Monte Carlo 
simulation 
Society 1999 £1,236 LYS, £1,097 per QALY, 70% 
probability intvn will be ≤ £5,000 per 
QALY 
€ 1,569 per QALY gained 
Eddy 200581 
 
Lifestyle modification vs 
pharmacotherapy vs placebo 
for adults at risk for diabetes 
(re-analysis of Herman 
2005) 
Archimedes 
modelling 
Society, 
Health provider, 
High risk 
individual 
2000 Lifestyle vs baseline US$24,523 per 
QALY 
Intensive lifestyle vs lifestyle 
$201,818 per QALY, sensitive to 
effectiveness estimates 
€ 24,691per QALY gained 
 
€203,197 per QALY gained 
intensive vs lifestyle 
Malone 200583 LOSE weight program with 
and without 
pharmacotherapy 
Bootstrapping 
ICERs, Monte 
Carlo 
simulations, 
1 year 
timeframe 
post-intvn 
Health provider 2004 US $ 194 per additional pound of 
weight lost (or $423 per Kg) when all 
health care costs included 
€ 178 per additional pound of 
weight lost 
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Abbreviations:  C/E – cost-effectiveness, QALY – quality-adjusted life year, CVD – cardiovascular disease, GP – general practitioner, ICER – incremental cost-effectiveness 
ratio, intvn – intervention, LYS – life years saved.  
 
# Average cost-effectiveness ratios reported only
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